(a) Hobbs FDR, Gensini G, Mancini GBJ, Manolis AJ, Bauer B, Böhler S, Genest J, Feldman R, Harvey P, Jenssen TG, Metcalfe M, Marques da Silva P
(b) Hobbs FDR, Gensini G, Mancini GBJ, Manolis AJ, Bauer B, Genest J, Feldman RD, Harvey P, Jenssen TG, Marques da Silva P

(a) Can combining different risk interventions into a single formulation contribute to improved cardiovascular disease risk reduction? Rationale and design for an international, open-label program to assess the effectiveness of a single pill (amlodipine/atorvastatin) to attain recommended target levels for blood pressure and lipids (The Jewel Program)
(b) International open-label studies to assess the efficacy and safety of a single-pill amlodipine/atorvastatin in attaining blood pressure and lipid targets recommended by country-specific guidelines: the JEWEL programme

(a) Int J Cardiol 2006;110:242–50
(b) Eur J Cardiovasc Prev Rehabil 2009;16:472–80

Hypertension, hypercholesterolaemia

To assess the effectiveness of a single pill containing amlodipine and atorvastatin in helping patients achieve BP and LDL-cholesterol targets as defined by local guidelines

Open

16 weeks

2245 patients (1138 JEWEL 1, 1107 JEWEL 2), aged 18–80 years, with hypertension and elevated cholesterol, both treated or untreated

Single-pill amlodipine and atorvastatin, 5/10 mg/day, titrated to 10/80 mg/day, at the discretion of the physician

2219 patients (1135 JEWEL 1, 1084 JEWEL 2) were included in the intention-to-treat analysis. 66.8% of patients in JEWEL 1 and 65.7% in JEWEL 2 achieved country-specific BP targets. 92% in JEWEL 1 and 74% in JEWEL 2 achieved LDL-cholesterol targets

JEWEL 1 was carried out in the UK and Canada, JEWEL 2 in 11 European countries